A holding company whose principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics.
31-Jan-2019 – 3.5p – £90.4m – PER n/a
Interim Results For The 6 Months To End October 2018 – Still not making a Profit.
I will cease coverage here until I see signs of a Profit, at least a forecast one.
Advertisement
